

Housing Enterprise Oversight proposes to amend 12 CFR part 1780 as follows:

PART 1780—RULES OF PRACTICE AND PROCEDURE

1. The authority citation for part 1780 is revised to read as follows:

Authority: 12 U.S.C. 4501, 4513, 4517, 4521, 4631–4641.

2. Revise subpart E of part 1780 to read as follows:

Subpart E—Civil Money Penalty Inflation Adjustments

§ 1780.80 Inflation adjustments.

The maximum amount of each civil money penalty within OFHEO's

jurisdiction is adjusted in accordance with the Federal Civil Penalties Inflation Adjustment Act of 1990, as amended by the Debt Collection Improvement Act of 1996 (28 U.S.C. 2461 *note*) as follows:

U.S. Code citation	Description	New adjusted maximum penalty amount
12 U.S.C. 4636(b)(1)	First tier	5,500
12 U.S.C. 4636(b)(2)	Second tier (Executive Officer or Director)	11,000
12 U.S.C. 4636(b)(2)	Second Tier (Enterprise)	27,500
12 U.S.C. 4636(b)(3)	Second Tier (Executive Officer or Director)	110,000
12 U.S.C. 4636(b)(3)	Second Tier (Enterprise)	1,150,000

§ 1780.81 Applicability.

The inflation adjustments in § 1780.80 apply to civil money penalties assessed in accordance with the provisions of 12 U.S.C. 4636 for violations occurring after January 4, 2001.

Dated: December 28, 2000.

Armando Falcon, Jr.,

Director, Office of Federal Housing Enterprise Oversight.

[FR Doc. 01–177 Filed 1–3–01; 8:45 am]

BILLING CODE 4220–01–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for two approved new animal drug applications (NADA's) from Pfizer, Inc., to Phoenix Scientific, Inc. **DATES:** This rule is effective January 4, 2001.

FOR FURTHER INFORMATION CONTACT: Norman J. Turner, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0214.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017–5755, has informed FDA that it has transferred to Phoenix Scientific,

Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457, ownership of, and all rights and interests in NADA 065–110 for Pro-Pen G (penicillin G procaine) in Aqueous Suspension and NADA 065–498 for Pen BP–48 (penicillin G benzathine/procaine). Accordingly, the agency is amending the regulations in 21 CFR 522.1696a and 522.1696b to reflect the transfer of ownership. The agency is also taking the opportunity to restructure the regulation to reflect current format.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 522.1696a is revised to read as follows:

§ 522.1696a Penicillin G benzathine and penicillin G procaine sterile suspension.

(a) *Specifications.* Each milliliter of aqueous suspension contains penicillin G benzathine and penicillin G procaine, each equivalent to 150,000 units of penicillin G.

(b) *Sponsors.* See sponsors in § 510.600(c) of this chapter for the conditions of use in paragraph (d) of this section as follows:

(1) Nos. 000008, 000856, 000864, 010515, and 049185 for use as in paragraph (d)(1) of this section.

(2) Nos. 000856 and 049185 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(2)(iii) of this section.

(3) Nos. 000864, 010515, and 059130 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(B), and (d)(2)(iii) of this section.

(c) *Related tolerances.* See § 556.510 of this chapter.

(d) *Conditions of use—(1) Horses, dogs, and beef cattle—(i) Amount—(A) Beef cattle.* 2 milliliters per 150 pounds of body weight intramuscularly or subcutaneously. Repeat dosage in 48 hours.

(B) *Horses.* 2 milliliters per 150 pounds of body weight intramuscularly. Repeat dosage in 48 hours.

(C) *Dogs.* 1 milliliter per 10 to 25 pounds of body weight intramuscularly or subcutaneously. Repeat dosage in 48 hours.

(ii) *Conditions of use.* Treatment of bacterial infections susceptible to penicillin G.

(iii) *Limitations.* In beef cattle, treatment should be limited to two doses. Not for use in beef cattle within 30 days of slaughter. Do not use in horses intended for food purposes. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Beef cattle—(i) Amount.* 2 milliliters per 150 pounds of body weight subcutaneously. Repeat dosage in 48 hours.

(ii) *Conditions of use.* (A) Treatment of bacterial pneumonia (*Streptococcus* spp., *Corynebacterium pyogenes*,

Staphylococcus aureus); upper respiratory infections such as rhinitis or pharyngitis (*Corynebacterium*); blackleg (*Clostridium chauvoei*).

(B) As in paragraph (d)(2)(ii)(A) of this section; and prophylaxis of bovine shipping fever in 300- to 500-pound beef calves.

(iii) *Limitations*. Limit treatment to two doses. Not for use within 30 days of slaughter.

3. Section 522.1696b is revised to read as follows.

§ 522.1696b Penicillin G procaine aqueous suspension.

(a) *Specifications*. Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.

(b) *Sponsors*. See sponsor numbers in § 510.600(c) of this chapter as follows:

(1) Nos. 010515, 053501, and 059130 for use as in paragraph (d) of this section.

(2) Nos. 000864 and 055529 for use as in paragraph (d)(2) of this section.

(c) *Related tolerances*. See § 556.510 of this chapter.

(d) *Conditions of use*—(1) *Dogs and cats*—(i) *Amount*. 10,000 units per pound body weight daily by intramuscular injection at 24-hour intervals. Continue treatment at least 48 hours after symptoms disappear.

(ii) *Indications for use*. Treatment of infections caused by penicillin-sensitive organisms.

(iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Cattle, sheep, swine, and horses*—(i) *Amount*. 3,000 units per pound body weight (1 milliliter per 100 pounds body weight) daily by intramuscular injection.

(A) For Nos. 000864, 010515, 053501, and 059130: Continue treatment at least 48 hours after symptoms disappear.

(B) For No. 055529: Continue treatment at least 1 day after symptoms disappear (usually 2 or 3 days).

(ii) *Indications for use*. Treatment of cattle and sheep for bacterial pneumonia (shipping fever) caused by *Pasteurella multocida*; swine for erysipelas caused by *Erysipelothrix insidiosus*; and horses for strangles caused by *Streptococcus equi*.

(iii) *Limitations*. Not for use in horses intended for food.

(A) For Nos. 000864, 010515, 053501, and 059130: Do not exceed 7 days of treatment in nonlactating dairy and beef cattle, sheep, and swine, or 5 days in lactating cattle. Milk that has been taken during treatment and for 48 hours after the last treatment must not be used for food. Discontinue treatment for the

following number of days before slaughter: Nonruminating cattle (calves)—7, all other cattle—4, sheep—8, and swine—6.

(B) For No. 055529: Treatment should not exceed 4 consecutive days. Milk that has been taken during treatment and for 72 hours after the last treatment must not be used for food. Discontinue treatment for the following number of days before slaughter: Cattle—10, sheep—9, and swine—7.

Dated: December 12, 2000.

Melanie R. Berson,

Acting Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 01-72 Filed 1-3-01; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524

Ophthalmic and Topical Dosage Form New Animal Drugs; Gentamicin Sulfate, Mometasone Furoate, Clotrimazole Otic Suspension

AGENCY: Food and Drug Administration

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for veterinary prescription use of gentamicin/mometasone/clotrimazole otic suspension to treat otitis externa in dogs.

DATES: This rule is effective January 4, 2001.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7540.

SUPPLEMENTARY INFORMATION: Schering-Plough Animal Health Corp., 1095 Morris Ave., Union, NJ 07083, filed NADA 141-177 that provides for veterinary prescription use of Mometamax™ gentamicin sulfate/mometasone furoate/clotrimazole) Otic Suspension for the treatment of otitis externa associated with yeast (*Malassezia pachydermatis*) and/or bacteria susceptible to gentamicin in dogs. The NADA is approved as of December 5, 2000, and the regulations are amended in 21 CFR 524 by adding § 524.1044h to reflect the approval. The

basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning December 5, 2000, because the application contains substantial evidence of effectiveness of the drug involved, or any studies of animal safety, required for approval of the application and conducted or sponsored by the applicant.

The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 524

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 524 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 524.1044h is added to read as follows:

§ 524.1044h Gentamicin sulfate, mometasone furoate, clotrimazole otic suspension.

(a) *Specifications*. Each gram contains gentamicin sulfate, United States Pharmacopeia (USP) equivalent to 3-milligram (mg) gentamicin base, mometasone furoate monohydrate